Peter Loeb, MD
Orthopaedic Surgery · Tallahassee, FLNPI 1306848445
Payments from drug & device makers
Across 156 payments — averaging $152.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CGG Medical Inc$16K
- Arthrex$6K
- Smith+Nephew$670
- Medical Device Business Services, Inc.$260
- Johnson & Johnson$177
- Avanos Medical$134
- plus $379 from 13 others
What the payments were for
- Travel & lodging$17,90375%
- Food & beverage$4,62219%
- Education$1,3376%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CGG Medical Inc | 34 | $16,400 |
| Arthrex | 88 | $5,842 |
| Smith+Nephew | 7 | $670 |
| Medical Device Business Services, Inc. | 2 | $260 |
| Johnson & Johnson(2 entities) | 4 | $177 |
| Avanos Medical | 2 | $134 |
| Bioventus LLC | 2 | $65 |
| Pacira Pharmaceuticals Incorporated | 3 | $50 |
| Heraeus Medical, LLC. | 2 | $42 |
| DJO, LLC | 1 | $35 |
| Pacira Therapeutics, Inc. | 2 | $33 |
| Convatec Inc. | 2 | $26 |
| Linvatec Corporation | 1 | $25 |
| Vericel Corporation | 1 | $22 |
| Axogen | 1 | $20 |
| Heron Therapeutics, Inc. | 1 | $17 |
| Orthofix Medical, Inc. | 1 | $16 |
| Ultragenyx Pharmaceutical Inc. | 1 | $15 |
| Zimmer Biomet | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$23,862 in reported general payments places this provider in the 75th percentile of 1,263 orthopaedic surgery providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Celecoxib | 118 | $2,239 |
| Cephalexin | 124 | $684 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 31 | $469 |
| Azithromycin | 12 | $397 |
| Cefadroxil | 47 | $350 |
| Meloxicam | 59 | $300 |
| Tramadol Hcl | 55 | $214 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 18 | $186 |
| Baclofen | 18 | $157 |
| Hydromorphone Hcl | 22 | $156 |
Paid to pharmacies, not to this prescriber.
Other orthopaedic surgery in Tallahassee
- Andrew CooperClearwater$102M
- Richard HynesMelbourne$35M
- Mark FrankleTemple Terrace$31.4M
- David WatsonTemple Terrace$21M
- Roy SandersTemple Terrace$19.6M
- George HaidukewychOrlando$10M
- Martin RocheFt. Lauderdale$7.3M
- Robert SantrockFernandina Beach$7.3M
- Steven LyonsTampa$6.8M
- Derek CuffVenice$6.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.